Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
  1. pmc.ncbi.nlm.nih.gov

    Remdesivir was discontinued early after kidney disorder onset, with a median treatment duration of 3 (interquartile range, 1-4) days. In the vast majority of cases (316 [96.6%]), no other drug was suspected in the onset of kidney disorders. Reactions were serious in 301 (92.0%) cases, with a fatal outcome for 15 (4.6%) patients.
  2. pubmed.ncbi.nlm.nih.gov

    The combination of the terms "acute renal failure" and "remdesivir" yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20-fold (20.3; confidence interval 0.95 [15.7-26.3], P < 0.0001]) that of comparative drugs.
    Author:Alexandre O Gérard, Audrey Laurain, Audrey Fresse, Nadège Parassol, Marine Muzzone, Fanny Rocher, Vi...Published:2021
  3. jamanetwork.com

    Remdesivir is a broad-spectrum antiviral that reduces hospitalization and may decrease mortality among noncritically ill inpatients with COVID-19. 1,2 Remdesivir is not recommended for use in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min1.73 m 2 owing to the presence of excipients 3 that may accumulate in kidney dysfunction and worsen kidney or hepatic ...
  4. pmc.ncbi.nlm.nih.gov

    Patients with chronic kidney disease (CKD), especially those with end-stage renal disease (ESRD), are susceptible to the development of severe coronavirus disease 2019 (COVID-19), ... Remdesivir is a nucleotide analog that inhibits viral RNA-dependent RNA polymerase (RdRp) and that was issued an emergency use authorization by the U.S. Food and ...
  5. pmc.ncbi.nlm.nih.gov

    Abstract Objectives. Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there are concerns about the detrimental effects of remdesivir on kidney function which might consequently lead to Acute Kidney Injury (AKI).
  6. kidneymedicinejournal.org

    May 3, 2024There were 200 individuals with admission eGFR <60 mL/min/1.73 m 2 or kidney failure receiving kidney replacement therapy who received remdesivir within 72 hours of admission and 555 potential historical comparators who met inclusion criteria ().A sufficiently close match was found for 198 of the 200 (99%) remdesivir-treated patients, who were variably matched to 335 historical comparators.
  7. pubmed.ncbi.nlm.nih.gov

    The most frequent events were acute kidney injury (338; 11.6%), renal impairment (86; 2.9%), and renal failure (53; 1.8%). Versus hydroxychloroquine, lopinavir/ritonavir, or tocilizumab, the use of remdesivir was associated with an increased chance of reporting renal and urinary disorders regardless of gender and age of patients (2.53; 95%CI: 2 ...
  8. pubmed.ncbi.nlm.nih.gov

    Nov 22, 2024Methods: In REDPINE, a phase 3, randomized, double-blind, placebo-controlled study, participants aged ≥12 years hospitalized for COVID-19 pneumonia with acute kidney injury, chronic kidney disease, or kidney failure were randomized 2:1 to receive intravenous remdesivir (200 mg on day 1; 100 mg daily up to day 5) or placebo (enrollment from ...
  9. frontiersin.org

    Acute kidney injury (AKI) is a common complication among patients with the novel coronavirus (COVID-19). COVID-19 along with AKI usually resulted in a poor prognosis for those affected. Remdesivir is a novel antiviral drug that was urgently approved for the treatment of COVID-19. In the current study, safety data of remdesivir were limited.

    Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX